# Council memo — 2026-08-17 (memo 3 of 3) — **TEST / EVALUATION RUN**

> **Read this label first.** This is a **live test of the redesigned Stock
> Selection Council method** (`.claude/agents/council.md`, rewritten this
> session), run for real against today's actual data. It is a genuine
> analytical output — every number traces to a file fetched this sweep — but
> it is **not this session's operative sweep memo**. That is
> `reports/2026-08-17-council-memo-2.md`, produced under the previous method
> and still the standing set of calls. Where this memo disagrees with memo 2
> (it does, on ABB.ST), the disagreement is stated openly and memo 2 remains
> operative unless you decide otherwise. Nothing here needs acting on with a
> normal sweep's urgency.

*Structured synthesis of this system's own agents' analysis. Not advice from
a licensed advisor. Sources read this sweep:
`data/cache/snapshots/20260817T111313.json`,
`data/cache/screens/20260817T111504-screen.json` (all three lists),
`data/cache/watchlist.json` (67 entries), `data/portfolio.json`,
`data/company_profiles/*.json`, `data/investor_profile.json`,
`data/cache/definitions.json`, `data/cache/backtests/20260817T1117*.json`,
`data/cache/excel_import/latest-summary.json`, `OPEN_ITEMS.md`.*

`journal` ran in session-start mode at the top of this session. Its
reconciliation is a separate end-of-sweep artifact in `SESSION_LOG.md`, per
`OPEN_ITEMS.md` P2 item 3 — not blocked on here.

**Blocking-question check.** No open item holds blocking status.

**Candidate universe evaluated: 76 names.** 10 current holdings with an
actual ticker or fund identity (cash, the tax reserve and the frozen SEB
Osteuropafond excluded — no buy/sell decision exists for them) + all 67
watchlist entries from `scout`'s screen, across **all three** of its lists:
32 Passed, 19 Missing-data, 16 Failed. One overlap (INVE-B.ST vs the held
INVE-A.ST) counted once as a distinct security.

---

## 1. Position report

Snapshot `20260817T111313.json` · previous `20260817T061032.json`

> **Provenance note.** This run also had no shell access, so the table is
> the same reconstruction memo 2 used — arithmetic on fetched snapshot values
> using `position_report.py`'s own conventions, cross-checked to reconcile
> exactly against the portfolio agent's independently-computed totals (Avanza
> ISK 184,352.65 SEK; full portfolio ~218,826 SEK; equity 67.55%; crypto
> 4.13%; cash 20.93%). Same snapshot, same day, no new prices — the table is
> unchanged from memo 2 by construction, not by copying a stale figure.
> Re-run the script next sweep.

| Position | Price | Δ vs this morning | Δ vs cost | 52w percentile | Value (SEK) | Source |
|---|---|---|---|---|---|---|
| Handelsbanken A (1 sh) | 148.30 | +0.5% | **+14.7%** | **95.7%** | 148.30 | fetched |
| Investor A (5 sh) | 406.70 | -0.1% | **+40.1%** | 91.4% | 2,033.50 | fetched |
| Volvo B (13 sh) | 340.20 | +0.0% | **-7.4%** | 73.5% | 4,422.60 | fetched |
| Atlas Copco B (27 sh) | 181.15 | -0.7% | -0.1% | 92.6% | 4,891.05 | fetched |
| **AstraZeneca (5 sh)** | **1,480.00** | **-2.2%** | **-2.0%** | **20.5%** | 7,400.00 | fetched |
| Alfa Laval (9 sh) | 557.20 | -1.0% | -3.0% | 79.6% | 5,014.80 | fetched |
| ABB (4 sh) | 971.60 | -1.0% | +2.6% | 80.2% | 3,886.40 | fetched |
| Avanza Auto 3 (fund) | no data | — | +65.2% | — | 16,191.00 | book value |
| Avanza Global (fund) | no data | — | +0.0% | — | 119,999.00 | book value |
| **COIN-XBT.ST** | **SOLD 2026-08-17** | — | **+27.0% realized** | — | **0** | user-reported, 6 × 2,561 |
| ETH (0.50185, self-custody) | 17,992.33/unit | +0.3% | no data (P1) | — | 9,029.46 | fetched (CoinGecko × sek_per_eur 10.9523) |
| Avanza ISK cash | — | — | — | — | **20,366** (only 15,366 traced) | Excel delta |
| HB tax reserve + checking | — | — | — | — | 11,363.76 | confirmed |
| PayPal (1,177.49 USD + 266.88 EUR) | — | — | — | — | 14,079.79 | confirmed |

**Full portfolio 218,826 SEK** (full-portfolio convention per
`data/cache/definitions.json`, D3). Equity 67.55% · crypto 4.13% · cash
20.93%. BTC 54,838 EUR (-49.1% off ATH), ETH 1,642.79 EUR (-61.2% off ATH),
Fear & Greed 31 ("Fear").

**Reading it.** Nothing in the equity book moved more than 2.2% today, so
price is not the story — the structural move is: **you sold the entire
Bitcoin certificate**, which realized 3,265.98 SEK tax-free, cut annual fee
drag 68% to 0.084%, and flipped crypto from 11.43% over-target to 4.13%,
5.9pp under. The index funds (Avanza Global at 54.84% of the portfolio, Auto
3) are deliberately buy-and-hold, both INTACT, one line each is the right
amount of attention.

**Does any move contradict a thesis?** One, in the helpful direction:
**AstraZeneca fell to the 20.5th percentile of its 52-week range and below
its 1,509.70 cost basis** while every fundamental input held (revenue +6.4%,
fourth consecutive rising year, operating margin 23.5%, PEG 1.34, beta
0.211). Thesis INTACT — price moved, information did not. The mirror image
is **Handelsbanken A at 95.7% of range** on revenue -3.8% YoY, PEG 20.4 and
an analyst "underperform": the upside the original thesis named has already
been taken, and it is one share worth 148.30 SEK.

---

## 2. Top opportunities — Stock Selection Council output

### Step 1 — seven independent analyst passes

*Each voice reviewed the full 76-name universe and wrote its picks before
seeing any other voice's conclusions. Convictions are 1-10 and were not
adjusted for consistency afterwards.*

---

#### Voice 1 — Fundamental / Quality Investor

**BUY 1 — GOOGL. Conviction 8.**
ROE 48.7%, operating margin 34.0%, ROIC ~28.6% (est.), debt/equity 18.9, and
net cash of ~122bn USD — the strongest balance sheet in the universe attached
to a business still growing revenue 24.2%. *Why now:* four straight years of
rising revenue (283 → 307 → 350 → 403bn) with no year of margin
deterioration. *Risks:* trailing FCF is only 22.7bn against 163bn of capex —
the one quality metric that matters most is the one currently compressing,
and I cannot tell whether that is a cycle or a permanent step-change.
*Missing data:* no multi-year FCF/capex series (structural Yahoo limit); no
interest expense; profit margin 54.8% exceeds operating margin 34.0%, which
means the bottom line contains something non-operating I cannot see.
*Would most change my view:* a real 4-year FCF series.

**BUY 2 — NOVO-B.CO. Conviction 7.**
Gross margin 82.0%, operating margin 42.5%, ROE 59.8%, ROIC ~35.8% (est.),
and four consecutive years of revenue growth (177 → 232 → 290 → 309bn DKK).
On the numbers alone this is the highest-quality business in the universe
that is not a US mega-cap. *Risks:* ttm revenue growth is +2.1% against a
4-year CAGR near 20% — an abrupt stall the quality record does not explain.
D/E 63.3 is the highest of my picks. *Missing data:* no `sek_per_dkk` in this
snapshot, so I cannot express any figure in the base currency; no pipeline,
patent-cliff or competitive data of any kind. *Would most change my view:*
one more quarter of revenue, to see whether +2.1% is a floor or a slope.

**BUY 3 — ATCO-B.ST (existing holding). Conviction 6.**
Purely on business quality: ROE 25.7%, ROIC ~39.7% (est.), gross margin
42.2%, D/E 33.7, and FCF margin 15.3% — the best cash conversion in the
entire individual-stock sleeve. *Why now:* ttm revenue has recovered to +9.1%
after FY2025's -4.8%. *Risks:* the recovery is one trailing figure, not a
reported quarter. Price is explicitly not my lens; see Voice 2.
*Missing data:* multi-year FCF; the 2026-08-17 `swedish-equity-review`
(62/100, `data/company_profiles/ATCO-B.ST.json`) gives me the best coverage
of any Nordic name here and I am leaning on it.

**BUY 4 — LIFCO-B.ST. Conviction 6.**
Serial acquirer with ROE 20.2%, ROIC ~14.6%, four straight years of revenue
growth (21.6 → 24.5 → 26.1 → 28.3bn SEK) and 14.2% FCF margin. *Risks:*
acquisition-driven compounding means goodwill quality and integration
discipline decide the outcome, and neither is visible in this data.

**SELL — ABB.ST. Conviction 5.**
ROE 32.6% reads as high quality, but FCF margin is **4.4%** — the worst of
any holding — against ATCO-B's 15.3% and ALFA's 6.9%. A business converting
4.4% of revenue to free cash while carrying the heaviest capex load of the
three is not the quality the ROE implies. Score 51/100 on this session's
review, lowest of the three P6 industrials.

**SELL — SHB-A.ST. Conviction 5.**
Revenue -3.8% YoY, ROA 0.63%, ROIC ~1.2% (est.). Nothing in the quality data
supports holding it; the position is one share.

---

#### Voice 2 — Valuation Investor

**BUY 1 — TTE (TotalEnergies). Conviction 7.**
P/E 11.06, forward 9.16, PEG 0.72, P/B 1.53, 4.8% dividend at a 49.3% payout,
13.5bn USD trailing FCF. That is the highest defensible earnings yield (~9%)
in the passed universe. *Why now:* forward multiple is below trailing, which
means consensus expects earnings **up**, not down — the opposite of what most
cheap-looking names here show. *Risks:* revenue has fallen four consecutive
years (263 → 219 → 196 → 182bn) and the price sits at **80.6% of its 52-week
range** — I am not buying a forgotten asset, I am buying a cheap multiple near
a high. Oil majors are structurally cheap on P/E; that is a sector feature,
not a signal. *Missing data:* no reserve life, no breakeven oil price, no
capex plan.

**BUY 2 — NOVO-B.CO. Conviction 7.**
P/E 11.17 attached to 42.5% operating margins and 59.8% ROE is a combination
that does not normally coexist. At the **37.9th percentile** of its 52-week
range and -28.1% off its high. *This is the case where quality and price do
NOT pull apart* — which is precisely why it is my top-ranked new name and not
merely my cheapest. *Risks, stated as the counterweight:* **PEG 3.11**. The
P/E is only cheap if growth resumes; on ttm growth of +2.1% the multiple is
roughly fair, not cheap. Those two readings genuinely conflict and I am not
averaging them — the pick is a bet that the trailing four-year record is more
informative than the trailing four quarters. *Missing data:* no `sek_per_dkk`;
no fair-value estimate anywhere in this system (V2 Phase 2 unbuilt).

**BUY 3 — META. Conviction 6.**
P/E 22.2, forward 16.9, PEG 0.88 — and at the **27.6th percentile** of its
52-week range while revenue grew 28.0%. Falling price against accelerating
revenue is the specific pattern this lens exists to find. *Risks:* trailing
FCF 21.6bn against **108.7bn** of capex — the earnings in that P/E are not
currently converting to cash, and if the capex is permanent the multiple is
not what it appears.

**BUY 4 — GOOGL. Conviction 6.** PEG 0.94 on a 17.4x P/E with 48.7% ROE.
Same capex caveat as META, one notch less severe.

**Where quality and valuation pull apart — stated explicitly, as required:**
- **ATCO-B.ST**: excellent business (Voice 1's pick), P/E 33.2, PEG 2.38,
  92.6% of range. A great company at a price that is not a great investment.
- **ALFA.ST**: PEG **2.86** — the worst growth-adjusted value of the three
  P6 industrials *despite* the lowest headline P/E (28.3x), because ttm
  growth (7.7%) is lower than ATCO-B's (9.1%).
- **LIFCO-B.ST**: P/E 37.3 with forward P/E **39.6** — the forward multiple is
  *above* trailing, meaning consensus expects earnings to fall. A quality
  compounder priced for perfection.

**SELL — ABB.ST. Conviction 6.**
P/E 37.6, forward P/E 37.1 — **essentially flat despite 14.2% ttm revenue
growth**, which is a margin-compression signal, not a valuation. PEG 2.71,
80.2% of range, FCF margin 4.4%. There is no reading of this price I can
defend. *Missing/unreliable data, named:* Yahoo's raw P/S (49.6x) and P/B
(111.7x) for ABB are **FX-unit artifacts** (market cap in SEK, revenue and
book value in USD) — FX-corrected to ~5.2x and ~11.7x per
`data/company_profiles/ABB.ST.json`. Do not quote the raw figures.

**SELL — SHB-A.ST. Conviction 5.** PEG 20.4, 95.7% of range, revenue -3.8%.
Cheap-looking P/E (12.4) on a shrinking top line is the definition of cheap
for a reason.

*Data gaps most limiting me:* no fair-value / DCF anywhere; no NAV
discount/premium for holding companies (S6) — though I note P/B is a partial
proxy for *pure* investment companies (INDU-C.ST at **0.997x book**, INVE-A.ST
at **1.146x**), and explicitly **not** for Latour (2.85x), which owns operating
businesses outright.

---

#### Voice 3 — Growth / Opportunity Investor

**BUY 1 — NVDA. Conviction 7.**
Revenue +85.2% ttm on a four-year path of 27 → 61 → 130 → 216bn USD, ROE
114%, D/E 6.6, operating margin 65.6%. **Forward P/E 17.6 against a trailing
34.5 and PEG 0.62** — the cheapest forward multiple relative to growth in the
entire 76-name universe. *Risks:* that forward multiple is consensus
estimates, not a fact; one quarter of order deceleration re-rates it hard.
Price at 84.5% of range, beta 2.215. *Missing data:* no order book, no
backlog, no segment revenue, no customer concentration — for a name whose
whole case is forward trajectory, that is a serious gap.

**BUY 2 — TSM. Conviction 7.**
Revenue +36.0%, operating margin 60.3%, PEG 1.03, forward P/E 19.6 vs
trailing 32.2, four-year revenue 2.26 → 4.44 trillion TWD. The picks-and-
shovels position with the least substitutable role in the same trend NVDA
sells into. *Risks:* single-island geographic concentration, entirely
unpriceable from this data. P/B 88.9 is an FX-unit artifact, ignore it.

**BUY 3 — META. Conviction 6.**
Revenue +28.0%, four-year 117 → 135 → 165 → 201bn, forward P/E 16.9, and the
price at the 27.6th percentile. The only large-cap in the universe where
accelerating revenue and a falling price coincide right now.

**BUY 4 — VWS.CO (Vestas). Conviction 4 — genuinely 4, not padded to reach a
number.** Revenue +26.1%, PEG 0.85, forward P/E 17.1 vs trailing 25.2. But
gross margin is 14.7% and trailing FCF is 521m DKK on 20.3bn of revenue
(2.6%) with D/E 89.2 — growth without cash conversion. It is my third-best
genuine idea and a 4 is the honest number.

**On the existing book:** VOLV-B.ST is the only holding with a live growth
inflection — revenue growth flipped positive (+2.7% vs the -13% two-year
decline cited at purchase), forward P/E 13.7, PEG 1.42, analyst "buy". It is
two weeks held against its own three-month break condition, so I flag the
inflection and recommend nothing.

**SELL: none.** No holding fails on growth grounds in a way the other lenses
do not already cover better.

*Would most change my view:* forward revenue estimates and order backlog — I
currently infer both, opaquely, from forward P/E.

---

#### Voice 4 — Defensive / Risk Analyst

**What I am worried about:** DXY at 119.06 with Fed funds 3.63% against ECB
2.25% and Riksbank 1.75% — a wide, persistent rate differential. US CPI 3.54%
against a 3.63% policy rate is a real policy rate of roughly **+0.1%**:
barely restrictive, so inflation re-acceleration is a live risk, not a closed
one. VIX at 14.63 is complacency, not calm. And the specific portfolio risk is
not macro at all: **65.5% of the individual-stock sleeve is one bet on the
global capex cycle**, with zero staples, zero energy, zero telecom and a
single healthcare name.

**BUY 1 — AZN.ST (existing holding, add). Conviction 7.**
Beta 0.211, at the 20.5th percentile of its 52-week range, below its own cost
basis, revenue +6.4% across four consecutive rising years, PEG 1.34. It is
the cheapest genuinely defensive asset in the universe on a growth-adjusted
basis, and the portfolio already owns and understands it. *Risks:* the
holding's own recorded conditions — structural margin deterioration, a
dividend cut, or re-rating to a growth-like premium. None triggered.

**BUY 2 — PG. Conviction 6.**
Beta 0.377, 3.01% yield at a 64.3% payout, and — the reason it is here —
**the 22.4th percentile of its 52-week range**. It is the only defensive
staple in the universe trading near its low rather than its high: KO sits at
86.3%, JNJ at 87.4%. If you want ballast, buying it after it has already run
is the expensive way. *Risks, plainly:* PEG 4.14 and revenue +1.5%. You are
paying 21.8x for almost no growth. This is ballast, not a return engine, and
I am not going to pretend otherwise.

**BUY 3 — NOVO-B.CO. Conviction 6.**
Beta 0.349, 3.97% yield, healthcare, 37.9th percentile. Adds a second
defensive leg whose failure modes (GLP-1 competition, pricing) do not overlap
AZN's oncology/respiratory pipeline. *Risks:* D/E 63.3; ttm growth stall.

**Named and rejected — TEL2-B.ST. Conviction 3, and I want the rejection on
the record.** Beta 0.323 and a **6.37% dividend yield** is the textbook
defensive-ballast profile and it will pass any yield screen. But forward P/E
25.0 against a trailing 11.4 says the market expects earnings to roughly
halve; PEG 4.31; D/E 135.2; payout 58.0% of an earnings figure that is
expected to fall. That is a dividend-trap signature, not defense.

**SELL — ABB.ST. Conviction 6.**
Highest beta of the three P6 industrials (1.011), richest multiple, thinnest
cash conversion, and the largest single contributor to the concentration I am
most worried about.

**SELL — SHB-A.ST. Conviction 4.** Not a risk call: 148.30 SEK is 0.07% of
the portfolio and cannot affect the outcome, but it consumes a line of
attention every sweep.

*Missing data that would most change my assessment:* **revenue-by-currency for
every holding.** The scorecard's currency row is UNKNOWN, and in a DXY-119
regime the thing I most need to know — how much of the industrial sleeve's
earnings are USD-translated — is exactly the thing no source provides.

---

#### Voice 5 — Contrarian / Risk Taker

**BUY 1 — LATO-B.ST (Latour). Conviction 5.**
At the **13.7th percentile** of its 52-week range (193.65 against 184.55–250.80)
it is the single most beaten-down name in the entire Passed list — while the
Swedish investment-company peers it is habitually valued alongside sit near
highs: INVE-A.ST at 91.4%, INDU-C.ST at 76.3%. A ~60pp percentile dispersion
across broadly similar Swedish-industrial exposure is worth naming, not
ignoring. *Risks — the deterioration is real, this is not a free lunch:*
revenue -2.2%, ROE 10.3%, ROIC ~4.6% (est.), payout 65.6%. *Missing data:* no
NAV discount (S6), and here it matters more than usual — P/B 2.85 is
structurally uninformative for Latour because its wholly-owned industrial arm
is carried at cost, not marked to market. I am arguing dispersion, not value.

**BUY 2 — META. Conviction 6.**
The market is pricing 108.7bn of capex as permanently destroyed value while
revenue grows 28%. That may prove correct — but it is a nameable,
contested reason, not a deterioration story, and the price is at the 27.6th
percentile. This is what "unpopular for a reason the market may have
overweighted" looks like.

**BUY 3 — SAAB-B.ST. Conviction 4 — and I am arguing against `scout`'s own
threshold, deliberately.**
SAAB **failed** the screen on a single criterion: trailing P/E 52.29 above the
40.0 cap. That cap is calibrated for steady-state businesses. European defense
is in a multi-year, government-budget-driven order expansion in which trailing
earnings lag the order book *by design* — the threshold is measuring the
wrong window. That is a real argument and I make it. **Here is its honest
limit:** the screen file stores only the *failing reason* for failed names and
discards everything else, so this sweep has **no** revenue growth, margin,
forward P/E, FCF or backlog figure for SAAB. I can argue the threshold is
wrong; I cannot underwrite the company. Conviction stays 4 and my
recommendation is "fetch it properly," not "buy it."

**BUY 4 — NIBE-B.ST. Conviction 3.**
Post-heat-pump-boom bust: revenue down from 46.6bn (FY2023) to 40.8bn, ROE
7.8%, forward P/E 22.8 against a trailing 32.4. Genuinely unloved, and the
forward-below-trailing spread says consensus sees earnings recovering. But
nothing in this data says the cycle has turned. A 3 is a 3.

**SELL: none.** This voice's honest read on the portfolio's own losers runs
the other way — VOLV-B.ST at -7.4% below cost and AZN.ST below cost on
unchanged fundamentals are precisely the positions a contrarian holds, not
the ones a contrarian sells.

---

#### Voice 6 — Portfolio / Diversification Strategist

**The rule I am enforcing this sweep:** Avanza Global is **54.84%** of the
portfolio. AAPL, MSFT, GOOGL, NVDA, META, AMZN, V, JNJ, KO, PG and TSM are all
top-20 constituents of a broad global index fund. Buying any of them
individually **concentrates the portfolio, it does not diversify it** — a
good company duplicating an exposure already at its cap is a weaker pick here
than a merely-good one that fills a hole. That disqualifies eleven of
`scout`'s thirty-two Passed names from *this* lens regardless of their merit.

Actual holes: healthcare 3.4% of the portfolio (one name), energy **0%**,
staples **0%**, telecom **0%**, non-Nordic individual equity **0%**,
industrials **65.5% of the stock sleeve** (ACT), institution concentration
Avanza **84.25%** (breaches the 80% cap).

**BUY 1 — NOVO-B.CO. Conviction 7.**
Healthcare + Denmark + DKK, in one order. It adds a second defensive leg, a
non-SEK Nordic currency (the portfolio's individual sleeve is entirely SEK),
and a sector at 3.4%. On fit-adjusted grounds it is the best candidate in the
universe. *Risks:* DKK is EUR-pegged in practice, so the currency
diversification is thinner than it looks; and I cannot size it — no
`sek_per_dkk` in this snapshot.

**BUY 2 — AZN.ST (add). Conviction 7.**
Same structural logic, already owned, no new name to monitor, SEK-denominated
so it is executable today. Every krona into it mechanically reduces the
ACT-rated industrials share by growing the non-industrial denominator.

**BUY 3 — TTE. Conviction 5.**
Energy is 0% of the portfolio and is the one sector positively levered to the
single macro shock that would hit the equity sleeve **and** the crypto sleeve
simultaneously. Preferred over EQNR on P/B (1.53 vs 4.60) and on beta — EQNR's
reported beta of **-0.73** is not usable data for an integrated oil producer
and I am flagging it rather than using it. *Risks:* it adds a fourth cyclical
bet; the diversification is in the *driver*, not in the cyclicality.

**BUY 4 — ERIC-B.ST. Conviction 4.**
Swedish (which the user has stated a deliberate preference for backing) but
in communication equipment — a sector the individual sleeve has none of. ROE
26.1%, FCF margin 13.5%, D/E 37.7, at the 44.9th percentile. *Risks:* revenue
-6.1%; it diversifies sector but not currency or geography, so it is a half
solution.

**Named and rejected, with reasons:**
- **AZA.ST (Avanza Bank).** Screens well (ROE 39.1%, operating margin 63.5%,
  revenue +25.4%). Rejected: institution concentration is already **84.25%**
  at Avanza and breaching the 80% cap. Owning the platform's equity converts a
  custody concentration into a correlated *economic* one. Also forward P/E
  30.8 against trailing 22.4 — consensus expects earnings down.
- **INDU-C.ST (Industrivärden).** P/B 0.997 is genuinely interesting as a
  crude NAV proxy. Rejected on fit: its underlying holdings include **Volvo
  and Handelsbanken**, both already held directly. It would double the exact
  positions this portfolio is trying to dilute.
- **SU.PA (Schneider Electric).** A near-exact functional duplicate of ABB —
  same electrification/automation exposure, and at 94.3% of its 52-week range.
- **EQQQ / QQQ / VOO / CSPX / IWDA / VWCE.** Index products that overlap
  Avanza Global almost entirely. (Note separately: VOO and QQQ are
  US-domiciled and generally unavailable to EU retail under MiFID II/PRIIPs;
  EQQQ/CSPX/IWDA/VWCE are the UCITS forms, but three of the four returned 404
  this sweep.)

**SELL — ABB.ST. Conviction 6.** The sleeve's most redundant industrial —
ATCO-B, ALFA and the rejected SU.PA all cover overlapping ground — and its
lowest-scored (51/100).

*Missing data that would most change my ranking:* **look-through holdings for
Avanza Global and Avanza Auto 3.** My entire overlap argument above — which
kills eleven candidates and governs 71% of the portfolio — is reasoned from
how a global index is constructed, **not** from a fetched holdings list. That
is the largest unverified premise in this memo.

---

#### Voice 7 — Macro / Regime Analyst

**Regime read.** Neutral, tilting risk-on for developed equities: 10y-2y
spread **+0.48** (positively sloped, not recession-signalling), VIX **14.63**.
Against that, a real strong-dollar headwind: DXY **119.06**, Fed funds 3.63%
against ECB 2.25% and Riksbank 1.75%. US CPI 3.54% against a 3.63% policy
rate is a real policy rate near zero — inflation risk is not closed.
**Advantaged now:** energy (the only real-asset hedge in the universe),
low-beta defensives (volatility is cheap), USD revenue earners on translation.
**Disadvantaged:** crypto explicitly (Fear & Greed 31, BTC -49.1% / ETH -61.2%
off ATH; a strong dollar is the mechanical headwind), and long-duration
high-multiple equity if the 10y (4.63%) moves higher.

**BUY 1 — TTE. Conviction 6.** Beta 0.062. Energy is the one sector
positively levered to a CPI-above-target regime, and the portfolio holds none.
*Risks:* forward P/E 9.2 already prices a benign oil environment; a
demand shock in a strong-dollar world hits price and volume together.

**BUY 2 — AZN.ST. Conviction 6.** Beta 0.211 into a VIX of 14.63 is the
asymmetry worth buying when volatility is cheap. Stated plainly because it is
not always true: **this is a regime endorsement of a name that also passes on
fundamentals** — macro and company agree here, which is the easy case.

**BUY 3 — NVDA. Conviction 5 — and I am downgrading it on regime grounds
alone, which the method requires me to say out loud.** NVDA and TSM have the
strongest company-specific fundamentals in this universe (revenue +85.2% and
+36.0%, PEG 0.62 and 1.03). I am marking them down purely because they are
high-multiple, long-duration, USD-priced assets into a DXY-119 tape with a
4.63% 10-year. **That is a macro override of strong company fundamentals and
it should be read as exactly that**, not as a fundamental doubt. If you
disagree with my regime read, ignore this downgrade.

**SELL: none on regime grounds.** Specifically, I do **not** recommend selling
ETH despite crypto being the one part of this book squarely on the wrong side
of the regime. Fear & Greed 31 is moderate fear, not capitulation; the
holding's stated horizon is 3y+; and this system has no demonstrated
short-horizon timing edge. Regime should govern *sizing*, not liquidation.

*Missing data that would most change my assessment:* **Swedish CPI is stale at
period 2025M12 (S4, ~8 months old).** I cannot compute a real Swedish policy
rate, which means I cannot honestly regime-grade 65.5% of the individual-stock
sleeve. This is the fourth consecutive sweep this gap has capped a live call.
Also absent: credit spreads, PMI, unemployment (V2 Roadmap Phase 5).

---

### Step 2 — the Chairman: Top 5 Overall Opportunities

*Ranked by how much the evidence says they deserve your attention this sweep
— buys and sells both. Where a voice's stated motivation does not survive
contact with the numbers, I say so rather than averaging it in.*

```
#1 OPPORTUNITY: NOVO-B.CO — Novo Nordisk B
TYPE: new candidate (not currently held)
AGENTS IN FAVOR: Fundamental/Quality: 7, best non-US-mega-cap business in the
        universe on margins and ROE; Valuation: 7, P/E 11.2 attached to 42.5%
        operating margins at the 37.9th percentile of range; Defensive/Risk: 6,
        beta 0.349 plus a 3.97% yield in a sector the book barely holds;
        Portfolio/Diversification: 7, the single best fit-adjusted candidate —
        healthcare + Denmark + DKK in one order
AGENTS AGAINST / CAUTIOUS: Growth/Opportunity: did not pick it — ttm revenue
        +2.1% is not a growth story; Macro/Regime: neutral, no regime edge
        either way; Contrarian: did not pick it — -28% off high is a de-rating
        the market understands, not a mispricing it has ignored
STRONGEST CASE FOR: Valuation's, and it is the reason this is #1 rather than
        merely interesting — a P/E of 11.2 alongside a 42.5% operating margin
        and 59.8% ROE is a combination that does not normally coexist, and
        it does not require the quality lens and the price lens to disagree.
        Almost every other name in this universe forces that trade-off.
STRONGEST CASE AGAINST: Valuation's own counterweight, which I weight as
        heavily as its case: PEG 3.11. Voices 1, 2, 4 and 6 are all reading a
        four-year record (177 → 309bn DKK) that the trailing four quarters
        (+2.1%) already contradicts. If +2.1% is the new slope rather than a
        trough, an 11.2x P/E is roughly fair, and the entire pick evaporates.
        Four voices agreeing is not four pieces of evidence here — they are
        substantially reading the same historical series.
DATA GAPS: (1) No `sek_per_dkk` anywhere in this snapshot's macro block — I
        cannot state a SEK price, a share count, or a position weight. That is
        an execution blocker, not a rounding issue. (2) No pipeline, patent-
        expiry or competitive data of any kind — for a pharma whose growth
        just stalled, that is the specific thing I would need. (3) Avanza
        tradeability of a Copenhagen listing is presumed, not verified.
        Together these discount confidence by roughly two points.
CHAIRMAN CONVICTION: 6
MAJOR UNCERTAINTY: Is the +2.1% ttm revenue figure a trough or a slope? One
        more reported quarter resolves it, and nothing else will.
FINAL CALL: HOLD-WATCH — with a dated unblock, not an indefinite one
PORTFOLIO-FIT REASONING: On standalone merit this outranks the AZN add: four
        of seven voices picked it, versus three for AZN. It still resolves to
        WATCH, and **not** because capital is unavailable — the external
        5,000 SEK is confirmed free (see #3's capital check). It resolves to
        WATCH because (a) I cannot compute a SEK price or share count from
        this sweep's data, so no order can be sized; (b) tradeability is
        unverified; and (c) the growth-stall uncertainty is resolvable by
        waiting one quarter at essentially no cost, since the portfolio
        already holds a defensive healthcare position rather than a hole. If
        `sek_per_dkk` is added to the fetcher, Avanza tradeability is
        confirmed, and the next reported quarter does not deteriorate further,
        this becomes the leading non-industrial candidate for the following
        contribution — ahead of a second AZN add.
HORIZON: Long (3y+)
```

```
#2 OPPORTUNITY: ABB.ST — ABB (Nasdaq Stockholm cross-listing)
TYPE: existing holding — 4 shares, 3,886.40 SEK, 1.78% of portfolio
AGENTS IN FAVOR (of holding/adding): none. Not one of the seven voices picked
        ABB as a buy candidate at any conviction.
AGENTS AGAINST / CAUTIOUS: Fundamental/Quality: 5 SELL, FCF margin 4.4% is
        the worst in the book and undercuts the 32.6% ROE; Valuation: 6 SELL,
        P/E 37.6 with a *flat* forward P/E of 37.1 despite 14.2% ttm revenue
        growth — a margin-compression signal, not a valuation;
        Defensive/Risk: 6 SELL, highest beta, richest multiple, thinnest cash
        conversion of the three industrials; Portfolio/Diversification: 6
        SELL, the most redundant industrial in a sleeve already 65.5%
        industrial
STRONGEST CASE FOR (holding): none of the seven made one. The strongest
        argument for holding comes from outside this method — memo 2's Call 4,
        which is a *discipline* argument rather than a view about ABB: the
        holding's own `break_conditions`, written this morning from real
        Finansinspektionen data, require the insider-selling pattern to
        continue into a **second** FI pull before hardening to an active
        reduce. This was the first pull.
STRONGEST CASE AGAINST: Valuation's, and it is the one that matters because
        it does not touch the insider condition at all. A forward P/E
        (37.1) that is flat against trailing (37.6) while revenue grows 14.2%
        means the market is pricing zero EPS growth from double-digit revenue
        growth — i.e. margin compression. Combined with a 4.4% FCF margin,
        the price requires an improvement the cash flow statement is not
        showing. **This case is independent of the insider signal**, and
        therefore independent of the break condition memo 2 declined to fire.
DATA GAPS: Raw Yahoo P/S (49.6x) and P/B (111.7x) are USD/SEK unit artifacts
        and unusable; FX-corrected to ~5.2x / ~11.7x. No multi-year FCF series
        to confirm 4.4% is structural rather than one heavy capex year. No
        second FI insider pull yet. These lower confidence but do not change
        direction — the P/E, forward P/E and FCF margin are all clean.
CHAIRMAN CONVICTION: 6
MAJOR UNCERTAINTY: Whether the 4.4% FCF margin is a capex cycle or a
        structural conversion problem. A real multi-year FCF series settles it;
        this system cannot fetch one (Yahoo limitation — needs the company's
        own cash flow statement via the `pdf` skill).
FINAL CALL: SELL — and this **diverges from memo 2's same-day HOLD**, which I
        am flagging rather than smoothing
PORTFOLIO-FIT REASONING: Two constraints shape this into a *rotation*, not a
        liquidation. First, cash is already 20.93% against a 5% target — the
        largest single deviation on the scorecard — so selling ABB into cash
        makes the worst-graded dimension worse. The sale is only correct paired
        with a destination, and the destination is non-industrial (AZN.ST
        today, NOVO-B.CO once #1 unblocks). Second, at 1.78% of the portfolio
        this is a ~3,886 SEK trade whose courtage is a real fraction of the
        benefit; it belongs folded into the next rebalancing, not executed as
        a standalone order. **On the divergence:** memo 2 was correctly
        reasoned on its own grounds — you do not fire a break condition on the
        first observation of a signal it explicitly says needs two. What the
        seven-lens method adds is that four voices reach SELL by routes that
        never invoke the insider signal at all. That is new information, not
        a re-argument. Treat memo 2 as operative unless you choose to adopt
        this read; if you do, ABB is the funding source for the next
        non-industrial buy.
HORIZON: Medium (6mo–3y)
```

```
#3 OPPORTUNITY: AZN.ST — AstraZeneca
TYPE: existing holding — 5 shares, 7,400 SEK, 3.38% of portfolio
AGENTS IN FAVOR: Defensive/Risk: 7, cheapest genuinely defensive asset in the
        universe on a growth-adjusted basis (beta 0.211, PEG 1.34, 20.5th
        percentile); Portfolio/Diversification: 7, every krona in mechanically
        reduces the ACT-rated industrials share and it is executable today in
        SEK; Macro/Regime: 6, beta 0.211 into a VIX of 14.63 is the asymmetry
        worth owning when volatility is cheap
AGENTS AGAINST / CAUTIOUS: none. Fundamental/Quality, Valuation, Growth and
        Contrarian each ranked other names higher, but **not one voice argued
        against it.** Stated plainly because it is uncommon: this candidate is
        genuinely one-sided across seven independent lenses.
STRONGEST CASE FOR: Portfolio/Diversification's, because it is a portfolio
        argument rather than a stock argument — this is the only available
        purchase that improves two ACT-rated scorecard dimensions at once
        (equity underweight and industrials concentration). Every alternative
        worsens at least one.
STRONGEST CASE AGAINST: The one nobody made, so I will: "price down, thesis
        intact" is what a value trap looks like from the inside. The
        distinguishing test is whether fundamentals moved with the price, and
        here they did not — revenue +6.4% across four consecutive rising fiscal
        years (44.4 → 45.8 → 54.1 → 58.7bn), operating margin 23.5%, payout
        47.4%. A -2.2% intraday move against that record is price, not
        information. The objection is answerable, and answered.
DATA GAPS: No fair-value estimate (V2 Phase 2). Yahoo's raw P/S (37.7x) and
        P/B (45.9x) for AZN show the same currency-mismatch signature as ABB
        and HEXA-B — do not use them. Neither gap touches the case, which
        rests on P/E, PEG, beta, revenue history and range percentile, all
        clean.
CHAIRMAN CONVICTION: 8
MAJOR UNCERTAINTY: Whether today's -2.2% reflects information not in this
        snapshot. The holding's own break conditions are the control.
FINAL CALL: BUY — 3 shares at ~1,480 SEK ≈ 4,440 SEK
PORTFOLIO-FIT REASONING: Takes the position to 8 shares, ~11,840 SEK, ~5.4% of
        the portfolio — inside the 15% single-position cap and inside the
        "normal" 3–8% band. Healthcare rises from one small position to a real
        second leg. Funded by external money, so `profit_recycling_rule` does
        not govern it and no tax event or wrapper question arises. This
        **independently reproduces memo 2's Call 3 via a different method**,
        which is the useful part of running the test: two structurally
        different processes over the same data converged on the same name.
HORIZON: Medium (6mo–3y) for the entry; the holding's own stated horizon is
        3–5 years
```

**Capital-availability check for #3.** Verified against **this sweep's**
portfolio-agent output, not carried from a prior memo: Avanza ISK cash reads
20,366 SEK of which only **15,366 SEK traces cleanly** to today's confirmed
6 × 2,561 SEK sale — and that 15,366 is already committed by memo 2 (2,513 to
Avanza Global, 12,853 earmarked for a verified BTC ETP with a hard 2026-09-03
default). The funding for this call is the **external 5,000 SEK** the user
stated this session is available now, which is a direct user statement and
outranks any file. **Caveat that matters:** it is coincidentally the same
amount as the unexplained +5,000 SEK Excel cash delta. If they are the same
money, this call is funded and nothing else changes; if they are not, verify
before assuming you have both.

```
#4 OPPORTUNITY: TTE — TotalEnergies
TYPE: new candidate (not currently held)
AGENTS IN FAVOR: Valuation: 7, highest defensible earnings yield in the
        universe (P/E 11.1, forward 9.2, PEG 0.72, P/B 1.53, 4.8% yield);
        Macro/Regime: 6, the only real-asset hedge against a CPI-above-target
        regime with a real policy rate near zero; Portfolio/Diversification:
        5, energy is 0% of the portfolio
AGENTS AGAINST / CAUTIOUS: Fundamental/Quality: did not pick it — ROIC ~9.9%
        and operating margin 12.8% are mediocre against everything else on my
        list; Growth: did not pick it — revenue has fallen four straight
        years; Defensive/Risk: did not pick it — a cyclical commodity producer
        is not defense, whatever its beta says
STRONGEST CASE FOR: Macro/Regime's, and it is a portfolio-insurance argument
        rather than a return argument — energy is the one sector positively
        levered to the single shock (inflation re-acceleration) that would hit
        the equity sleeve and the crypto sleeve *at the same time*. The book
        currently has no hedge for the correlated case.
STRONGEST CASE AGAINST: Valuation's own caveat, which I think outweighs its
        case here. Revenue has fallen four consecutive years (263 → 219 → 196
        → 182bn) and the price sits at **80.6% of its 52-week range**. Oil
        majors are structurally cheap on P/E — that is a permanent sector
        feature reflecting terminal-value uncertainty, not a signal. Buying a
        declining top line near a 52-week high because the multiple looks low
        is the exact error the cheap-multiple lens is prone to, and Valuation
        said so itself.
DATA GAPS: No reserve life, no breakeven oil price, no capex plan — for an
        integrated producer these are the figures that decide the thesis, and
        none is obtainable from free data. Also: EQNR's reported beta of -0.73
        is nonsense for an oil producer and made the peer comparison harder
        than it should have been. Confidence discounted materially.
CHAIRMAN CONVICTION: 5
MAJOR UNCERTAINTY: Whether the portfolio actually needs an inflation hedge —
        which depends on a Swedish real-rate read that S4 makes impossible
        (CPI stale at 2025M12). The case for this pick is partly blocked by
        the same data gap that caps the macro voice.
FINAL CALL: HOLD-WATCH
PORTFOLIO-FIT REASONING: The diversification argument is genuine — this is a
        real hole, not a manufactured one — but the entry is not, and there is
        no capital free for it in any case once #3 is funded. Concrete re-test
        conditions rather than an open-ended watch: revisit if TTE trades back
        below roughly the 65th percentile of its 52-week range (i.e. the
        multiple stops being the only attractive thing about it), **or** if a
        fixed Swedish CPI feed (S4) confirms an inflation regime the portfolio
        has no hedge against. Neither is a forecast; both are testable states.
HORIZON: Medium (6mo–3y)
```

```
#5 OPPORTUNITY: META — Meta Platforms
TYPE: new candidate (not currently held)
AGENTS IN FAVOR: Valuation: 6, PEG 0.88 with the price at the 27.6th
        percentile while revenue grew 28%; Growth/Opportunity: 6, the only
        large-cap where accelerating revenue and a falling price coincide;
        Contrarian: 6, unpopular for a nameable and contestable reason
        (capex), not for deterioration
AGENTS AGAINST / CAUTIOUS: Portfolio/Diversification: rejected outright — it
        is a top-20 constituent of Avanza Global, which is 54.84% of the
        portfolio, so buying it individually concentrates rather than
        diversifies; Macro/Regime: disadvantaged — long-duration,
        high-multiple, USD-priced into DXY 119 with a 4.63% 10-year;
        Defensive/Risk: beta 1.243 with 108.7bn of capex against 21.6bn of
        trailing FCF
STRONGEST CASE FOR: Growth's — a 28% revenue increase coinciding with a price
        at the 27.6th percentile of its range is a genuine divergence between
        fundamentals and price, and it is the only instance of that pattern
        among the universe's large caps this sweep.
STRONGEST CASE AGAINST: Portfolio/Diversification's, and it is decisive
        rather than merely cautionary. The single largest structural risk in
        this portfolio is not any stock — it is that 54.84% sits in one fund
        and the individual sleeve is 65.5% one bet. Adding a name already
        inside that 54.84% takes idiosyncratic single-company risk in exchange
        for **zero** new exposure. This is the clearest example in the memo of
        a genuinely good opportunity that the portfolio cannot use.
DATA GAPS: **The overlap claim is the load-bearing one and it is not
        verified.** No holdings list for Avanza Global was fetched; the
        argument is reasoned from how a broad global index is constructed.
        That premise governs 54.84% of the portfolio and is the largest
        unverified assumption in this memo — it should discount the fit-kill's
        confidence, not the opportunity's. Also: no multi-year FCF/capex
        series, which is exactly what would resolve whether the capex is a
        cycle or a step-change.
CHAIRMAN CONVICTION: 6 as a standalone opportunity · 2 as a portfolio action
MAJOR UNCERTAINTY: Whether META's capex is a temporary investment cycle or a
        permanent margin reset. No fetchable data answers it.
FINAL CALL: NO ACTION
PORTFOLIO-FIT REASONING: This entry exists in the Top 5 specifically to show
        the two-stage split working rather than collapsing. Three independent
        voices rank META a buy on its merits, and I agree with them — the
        opportunity is real. It still resolves to NO ACTION because the
        portfolio's binding constraint is overlap with a 54.84% index holding,
        not the quality of the idea. **A high-conviction opportunity resolving
        to NO ACTION on fit grounds is a correct output of this method, not a
        contradiction.** The same reasoning disqualifies AAPL, MSFT, GOOGL,
        NVDA, AMZN, V, JNJ, KO, PG and TSM from this portfolio, whatever
        Voices 1–3 and 5 think of them individually — eleven of `scout`'s
        thirty-two Passed names, killed by one structural fact.
HORIZON: Medium (6mo–3y)
```

---

### Other current-holding SELL flags that did not place in the Top 5

You get a direct answer to "should I sell anything" every sweep, not only when
a sell happens to rank.

| Holding | Flagged by | Chairman's call | Reasoning |
|---|---|---|---|
| **SHB-A.ST** | Fundamental (5), Valuation (5), Defensive (4) | **SELL — but fold into the next rebalancing, not as a standalone order** | Three voices flag it and none defends it: revenue -3.8%, PEG 20.4, ROIC ~1.2%, analyst "underperform", price at 95.7% of range. The honest limit is that it is **one share worth 148.30 SEK (0.07%)** — courtage on a standalone sale is a material fraction of the position. This is an attention-cost decision, not a return decision. Same conclusion memo 2 reached by a different route. |
| **ALFA.ST** | Valuation (quality/price divergence, no SELL) | **HOLD — no adds** | PEG 2.86 is the worst growth-adjusted value of the three P6 industrials despite the lowest headline P/E. But it scored highest of the three (63/100) with 10-of-10 real open-market insider buys and zero disposals since 2023, and a four-year revenue record with no down year. Expensive, not broken. |
| **ATCO-B.ST** | Valuation (quality/price divergence, no SELL) | **HOLD — no adds** | Voice 1 ranks it a top-4 *business* (ROIC ~39.7%, FCF margin 15.3%) and Voice 2 ranks its *price* unattractive (P/E 33.2, PEG 2.38, 92.6% of range). That is the divergence stated rather than averaged: hold the quality, do not pay up for more of it. |
| **INVE-A.ST** | none | **HOLD** | No voice recommended selling. Voice 6 rejected buying INDU-C.ST partly because it duplicates this position — which is an argument against the *new* name, not against the held one. The standing caveat is unchanged: no NAV discount has ever been obtained (S6), so the thesis remains plausible but not properly testable, and the 4.74x P/E is an accounting artifact, not cheapness. |
| **VOLV-B.ST** | none | **HOLD** | Two weeks held against its own three-month break condition. Voice 3 notes a genuine growth inflection (revenue +2.7% after a -13% two-year decline, forward P/E 13.7, PEG 1.42); Voice 5 notes it is the kind of position a contrarian holds at -7.4%. TOO_EARLY, and two weeks is not evidence. |
| **ethereum** | none | **HOLD — no adds** | Voice 7 explicitly declined to recommend selling on regime grounds, and I agree: Fear & Greed 31 is moderate fear, not capitulation, the stated horizon is 3y+, and this system has no short-horizon edge. The no-adds freeze stands on **P1** (cost basis unknown, so any disposal is an uncomputable 30% K4 event) — not on thesis grounds, since `portfolio.json` carries a full structured thesis dated 2026-08-12. |
| **Avanza Global / Auto 3** | none | **HOLD** | Both INTACT. Avanza Global at 54.84% is a literal breach of the 15% single-position cap but is a diversified index fund, not idiosyncratic risk. Fees 0.10% and 0.39%. |

**Also considered and not placed:** PG (Defensive, 6 — the only staple near its
low rather than its high, but PEG 4.14 and +1.5% revenue make it ballast, and
it duplicates an Avanza Global constituent), GOOGL (Fundamental 8 / Valuation
6 — killed by the same overlap fact as META), NVDA and TSM (Growth 7 each,
downgraded by Macro on regime grounds and by Diversification on overlap),
LATO-B.ST (Contrarian 5 — the 13.7th-percentile dispersion is real, but ROIC
~4.6% and no NAV figure make it an argument about price dispersion rather than
about value), SAAB-B.ST (Contrarian 4 — the threshold argument is sound, the
data to underwrite it does not exist this sweep).

---

## 3. Portfolio health scorecard

Carried over from the portfolio agent verbatim (via memo 2, same session, same
snapshot — not re-derived here).

| Dimension | Grade | Detail |
|---|---|---|
| Asset allocation vs targets | **ACT** | Equity **67.55%** vs 85% target — **-17.5pp / ~38,206 SEK short**. Cash **20.93%** vs 5% — **+15.9pp / ~34,868 SEK excess** |
| Crypto allocation | **WATCH** | 4.13% vs 10% target, -5.9pp. Flipped from overweight to underweight via today's sale |
| Equity sector concentration | **ACT** | Industrials **65.5%** of the individual-stock sleeve |
| Geography | **OK** | — |
| Currency exposure | **UNKNOWN** | No revenue-by-currency data for any holding |
| Single-position concentration | **WATCH** | Avanza Global **54.84%** — a literal breach of the 15% cap, but a diversified index fund, not single-company risk |
| Institution concentration | **ACT** | Avanza **84.25%**, breaches the 80% cap — byproduct of correct ISK consolidation |
| Fee drag | **OK** | **183.14 SEK/yr = 0.084%**, down 68% after the certificate sale |
| Wrapper efficiency | **OK** | 184,352.65 SEK in the ISK vs the 300,000 SEK allowance (P7 confirmed) — 115,647 SEK headroom |
| Drawdown-tolerance fit | **OK (provisional)** | Real backtest, 86 months: current mix -14.6%, adopted target -19.95%, both inside the stated -30%. Provisional — one 7.2-year path, no 2008, no fees/taxes/FX, and the target's max drawdown equals its worst rolling 12 months |

**Provisional on three unanswered `investor_profile.json` questions, named
rather than smoothed:**
- **Where is the emergency buffer held?** "3-6 months" is stated; the account
  is not. This decides whether the 11,363.76 SEK of HB cash is buffer or
  investable capital — and therefore whether cash is really 20.93%.
- **`horizon.primary_goal` is explicitly uncertain, and the liability currency
  with it.** If the Mediterranean-apartment option firms up, the future
  liability is EUR, which reverses the rationale for the SEK/Nordic tilt
  entirely. This bears directly on Voice 6's NOVO-B.CO ranking.
- **Currency exposure stays UNKNOWN** — no source gives revenue-by-currency.
  Voice 4 named this as the single metric that would most change its
  assessment in a DXY-119 regime.

**Structure (levers 1-2): nothing broke.** All capital is in the ISK; fee drag
0.084%. Reported only because that is the standing rule when nothing changes.

---

## Headline calls

Three from the Stock Selection Council, one from Portfolio Governance. Not a
recap of every voice.

1. **Buy 3 shares of AZN.ST (~4,440 SEK) with the external 5,000 SEK.**
   Zero dissent across seven independent lenses — genuinely uncommon.
   Confidence **High** · Horizon **Medium**. *(Reproduces memo 2's Call 3 via
   a different method — that convergence is the test's most useful result.)*
2. **ABB.ST is a SELL on this method's read, diverging from memo 2's HOLD.**
   Four voices reach SELL by routes that never touch the insider signal memo 2
   declined to fire on. Rotation, not liquidation — pair it with a
   non-industrial destination. Confidence **Medium** · Horizon **Medium**.
3. **NOVO-B.CO is the best fit-adjusted new candidate in the universe and is
   currently unbuyable by this system** — no `sek_per_dkk` means no SEK price,
   no share count, no order. Unblock it, then it leads the next contribution.
   Confidence **Medium** · Horizon **Long**.
4. **D4 (profit-recycling convention) still needs your answer** — see the
   Governance section below; it is the one live non-stock fork this sweep.
   Confidence **High** that it needs deciding · Horizon **Long**.

---

## Portfolio Governance Council — D4: what does `profit_recycling_rule` apply to?

*Non-stock decision, so the five-voice method, not the seven analyst lenses.*

**The Contrarian.** The rule's own words are "the money I make from this" —
that reads as gain, not gross proceeds, and the sweep-after-sweep attempt to
read it as gross proceeds is the system straining to make a bookkeeping rule
carry an allocation decision it was never written for.

**First Principles.** Two of the user's own written instructions collide. The
adopted target says hold 10% crypto; the recycling rule says crypto proceeds
go to the secure tier. Applied to a *full* sale, the gross-proceeds reading
mechanically guarantees the 10% target can never be met again. A rule that
makes a target unreachable is being asked to do a job it was not written for.

**The Expansionist.** Ignore the SEK constraint: the maximum-upside version is
to stop treating this as a bookkeeping question at all and write one line —
"the target governs sizing; the recycling rule governs surplus above target."
That resolves this instance and every future one, which the per-trade reading
does not.

**The Outsider.** Told cold: you wrote down that you want 10% in crypto, then
wrote down that crypto money should move to safer assets. Someone has to say
which comes first. Nobody has, for three sweeps.

**The Executor.** Pick one of three, today, in one sentence: (1) target
governs sizing, rule governs surplus — 12,853 SEK stays earmarked; (2) gross
proceeds — all 15,366 SEK to Avanza Global, crypto stays at 4.13%; (3)
realized gain only — 3,266 SEK to Avanza Global, 12,100 SEK free.

**The Chairman.**
```
ACTION: WATCH (blocked on your decision — no system action available)
POSITION: 15,366 SEK of traceable ISK cash, currently split 2,513 to Avanza
          Global + 12,853 earmarked, per memo 2's Call 2
TARGET: A single pinned convention in `data/cache/definitions.json`, in
        words, alongside the existing `investable_capital_convention`
REASON: (1) The two readings now differ by their largest margin ever —
        15,366 SEK gross vs 3,265.98 SEK realized gain — because the sale was
        full, not partial; (2) the gross-proceeds reading, taken literally,
        makes the adopted 10% crypto target permanently unreachable after any
        full sale, which is an allocation outcome being decided by a
        bookkeeping rule; (3) this is the third instance of the same
        ambiguity class (S12) and it recurs on every future trim.
THESIS STATUS: n/a — governance convention
WHAT CHANGED: Nothing new this sweep. The change was the full sale on
        2026-08-17, and it remains undecided.
BREAK CONDITION: If undecided by 2026-09-03, memo 2's earmark auto-converts
        to Avanza Global — which resolves the money but leaves the convention
        open for the next trim.
CONFIDENCE: High (that it needs your decision) / not applicable to the outcome
HORIZON: Long
```
**Capital-availability check:** no capital moves on this call. The 12,853 SEK
earmark is already sized against the traceable 15,366 SEK verified in this
sweep's portfolio-agent output.

---

## Open actions vs open decisions

**Open actions** — things you can just go do.

| ID | Action | Amount / detail | By when |
|---|---|---|---|
| **P3** | Execute the PayPal conversion (Option A, decided) and route the SEK into the ISK | 14,079.79 SEK gross / ~13,517 net at the 4% worst case | No deadline, but it recurs ~every 2 months |
| **S9(c)** | Verify the unexplained **+5,000 SEK** ISK cash delta against a live Avanza statement before treating it as deployable | 5,000 SEK | Before the next buy |
| **P6** | Re-pull the Finansinspektionen insider register for ABB.ST — the second pull is what its own break condition needs | — | Before 2026-09-03 |
| **S1** | Find and verify one physically-backed, EU/Nordic-domiciled BTC ETP tradeable on Avanza inside the ISK | Unblocks 12,853 SEK | 2026-09-03 hard default |
| **P1** | Dig out the ETH cost basis | — | Not urgent unless selling |
| **Watchlist** | Add MSCI, SNPS, ARM, SCCO, STL to the Excel Watchlist tab so they get screened | — | Before next sweep |

**Open decisions** — forks where the data does not pick one answer. Each with
concrete options, never left as a bare question.

**D4 — what does `profit_recycling_rule` apply to?** (S12)
- *Option 1 — target governs sizing, rule governs surplus above target.* The
  12,853 SEK earmark stands; crypto can return to 10%. Trade-off: you are
  choosing to prioritise a written allocation target over a written
  risk-reduction instinct.
- *Option 2 — gross proceeds.* All 15,366 SEK to Avanza Global; crypto stays
  at 4.13% indefinitely. Trade-off: simplest and most conservative, but the
  adopted 10% crypto target becomes decorative.
- *Option 3 — realized gain only.* 3,266 SEK to Avanza Global, 12,100 SEK free
  to redeploy anywhere. Trade-off: closest to the rule's literal wording,
  weakest risk-reduction effect.

**D-new — ABB.ST: memo 2's HOLD or this method's SELL?**
- *Option A — keep memo 2's HOLD.* Wait for the second FI insider pull before
  2026-09-03. Trade-off: consistent with a break condition written from real
  data, but ignores four voices whose case never invokes that condition.
- *Option B — adopt the SELL and rotate.* Sell 4 shares (~3,886 SEK), buy
  AZN.ST or hold for NOVO-B.CO once unblocked. Trade-off: acts on the
  valuation/FCF/redundancy case, at the cost of overriding a two-week-old
  condition on its first observation, plus courtage on a small position.
- *Option C — hold now, but pre-commit ABB as the funding source for the next
  non-industrial buy from any source other than new money.* Trade-off: gets
  most of the benefit with none of the timing risk; this is what memo 2
  effectively did and what I would default to if you do not want to choose.

**D-new — AZN.ST or NOVO-B.CO for the healthcare add?**
- *Option A — AZN.ST, 3 shares now (~4,440 SEK).* Executable today, SEK-priced,
  PEG 1.34, already understood. Trade-off: increases single-name concentration
  in a position already the largest true single company at 3.38%.
- *Option B — wait for NOVO-B.CO.* Better standalone ranking (four of seven
  voices), better absolute multiple, adds a genuinely new name and currency.
  Trade-off: not sizeable from this data (no `sek_per_dkk`), tradeability
  unverified, and the +2.1% growth stall is unresolved.
- *Option C — split.* Not available this sweep: 5,000 SEK cannot buy a
  meaningful position in both, and NOVO cannot be priced at all.

---

## Where the agents disagreed

**1. Voice 1 vs Voice 2 on ATCO-B.ST, ALFA.ST and LIFCO-B.ST — quality and
price pointing opposite ways on the same names.** Fundamental ranks ATCO-B a
top-4 business in the universe (ROIC ~39.7%, FCF margin 15.3%); Valuation
ranks its price unattractive (P/E 33.2, PEG 2.38, 92.6% of range). Same for
ALFA (PEG 2.86 — worse growth-adjusted value than ATCO-B *despite* a lower
headline P/E, because ttm growth is lower) and LIFCO (forward P/E 39.6 above
trailing 37.3). **Resolution: hold, do not add.** This is not a call that
needs resolving — a good business at a full price is a hold, and pretending
the two lenses agree would lose the actual information. Confidence **High**.

**2. Voices 1/2/4/6 vs Voice 3 on NOVO-B.CO — four voices reading a four-year
record the trailing four quarters contradict.** The quality, valuation,
defensive and diversification lenses all pick it; the growth lens declines it
because ttm revenue is +2.1%. **This is not four-to-one.** Voices 1, 2 and 4
are substantially reading the *same* historical revenue series, so they are
one piece of evidence wearing three hats. Voice 3 is reading a different,
more recent one. **Resolution: the disagreement is the finding — conviction 6,
not 8, and the call is WATCH pending one more quarter.** Confidence **Medium**.

**3. Voice 7 downgraded NVDA and TSM on regime grounds alone, and said so.**
These have the strongest company-specific fundamentals in the universe (PEG
0.62 and 1.03, revenue +85% and +36%). Macro marked them down purely for being
long-duration USD assets into DXY 119 with a 4.63% 10-year. **The method
requires this to be stated rather than buried in a score, and it is.** It also
does not matter to the outcome — Voice 6's overlap rule kills both regardless,
for a completely unrelated reason. Two independent objections converging on
the same answer is worth noticing.

**4. This memo vs memo 2 on ABB.ST.** Covered in full at Top-5 entry #2. In
short: memo 2 held on a *discipline* argument about a break condition; this
method sells on *valuation, cash conversion and redundancy* arguments that
never touch that condition. Both are defensible; they are answering different
questions. Confidence **Medium**, and memo 2 stays operative unless you choose
otherwise.

**5. `scout`'s screen labels vs what the data actually supports.** Three of
the "Missing data" names are missing only `debt_to_equity` — SEB-A.ST,
SWED-A.ST — which is a **structurally meaningless metric for a bank**. They are
effectively fully screened and were mislabelled by a filter that does not
apply to them. Conversely, KINV-B.ST "failed" on `profit_margins = 0.0`, which
is meaningless for an investment company. The screen's thresholds are right on
average and wrong for specific business models; treating a label as a verdict
would have silently removed four names from consideration. Confidence **High**.

**Where they agree, stated because it is uncommon.** **AZN.ST drew zero
dissent across seven independent lenses.** Three picked it; four ranked other
names higher; none argued against it. That is the only such case in the
universe this sweep, and it is why call 1 is the memo's only High-confidence
buy.

---

## Broken theses requiring a decision

From `thesis-review`, unsoftened. **None broken.**
- **WEAKENING (5):** SHB-A.ST, INVE-A.ST, ATCO-B.ST, ALFA.ST, ABB.ST.
- **INTACT (4):** AZN.ST, Avanza Auto 3, Avanza Global, ethereum.
- **TOO_EARLY (1):** VOLV-B.ST.
- **CLOSED (1):** COIN-XBT.ST, sold in full, +27.0% realized, tax-free.
- **The standing cross-holding pattern, carried unsoftened:** five of seven
  equity holdings still share the identical thin "Swedish track record"
  non-differentiated rationale, and four of those five sit at 79.6–95.7% of
  their 52-week range simultaneously. That is one bet placed five times, and
  it is a portfolio-construction problem rather than five independent stories.
  **This method sharpened it rather than resolving it:** across seven
  independent lenses, not one voice produced a *buy* case for any of the five.

---

## Rebalancing actions

| # | Action | SEK | Tax | Status |
|---|---|---|---|---|
| 1 | Move the external 5,000 SEK into the ISK; **buy 3 shares AZN.ST (~4,440)**, remainder to Avanza Global | 5,000 | No tax event on transfer | **Recommended — same as memo 2 Call 3** |
| 2 | Buy Avanza Global with part of the traceable sale proceeds | 2,513 | Tax-free (ISK) | Carried from memo 2 |
| 3 | Hold 12,853 SEK earmarked for a verified BTC ETP; auto-converts to Avanza Global 2026-09-03 | 12,853 | n/a | Blocked on S1 |
| 4 | Execute P3 PayPal conversion and route to ISK | 14,079.79 gross / ~13,517 net | No tax event | Decided — pending execution |
| 5 | **Sell 4 ABB.ST, rotate into non-industrial** | ~3,886 | Tax-free (ISK) | **This memo's divergent call — see D-new** |
| 6 | Close the 1-share SHB-A.ST position | 148.30 | Tax-free (ISK) | Fold into the next rebalancing; not worth standalone courtage |

---

## Timing collisions

No calendar agent ran this sweep. Carried from memo 2: **AZN.ST reported
earnings 2026-07-27**, so the recommended add does not land on a print. Note
that memo 2 flagged a central-bank decision within days of 2026-08-17 as a
consideration for the (rejected) BITC trade — it does not bear on a defensive
healthcare add with a 3–5 year stated horizon.

---

## Cost of being wrong

| Call | If wrong, realistic downside | Recoverable? |
|---|---|---|
| Buy 3 AZN.ST (~4,440 SEK) | A further 20% drawdown on the enlarged 11,840 SEK position ≈ **-2,370 SEK**, ~1.1% of the portfolio. It is a profitable, dividend-paying large-cap pharma with four years of rising revenue, not a binary. | **Yes** — fully |
| Sell ABB.ST (~3,886 SEK) and rotate | If ABB re-rates upward after sale, the opportunity cost on 1.78% of the portfolio is roughly **-400 to -800 SEK** over a year on any plausible move, plus courtage both ways. | **Yes** |
| Hold ABB.ST instead (memo 2's call) | If the insider cluster and margin compression are real, a 25% decline costs about **-970 SEK**. | **Yes** |
| Wait on NOVO-B.CO rather than buying now | Opportunity cost only — no capital is committed and no position is at risk. If it re-rates upward before the data gap closes, the cost is a missed entry, not a loss. | **Yes** |
| D4 left undecided past 2026-09-03 | 12,853 SEK auto-converts to Avanza Global. Downside is a **crypto allocation left 5.9pp under target by default** rather than by decision — no SEK loss, but an allocation set by a deadline instead of by you. | **Yes**, but only by an explicit later decision |
| Not selling SHB-A.ST | **Effectively zero** — 148.30 SEK. The cost is attention, not money. | **Yes** |

---

## Excel data gaps

Sourced verbatim from `data/cache/excel_import/latest-summary.json` (11:11 UTC
this session). Fix these in the workbook before the next sweep:

- `ALFA.ST: no 52-week range in Excel (confirmed data-provider gap for some
  Nordic-primary tickers, not a formula bug) - treated as no data, not
  blocking.`
- `ATCO-B.ST: P/E 2.05 is outside the 3-80 sanity range - treat as suspect,
  verify in Excel before using it.`
- `ATCO-B.ST: no 52-week range in Excel (confirmed data-provider gap for some
  Nordic-primary tickers, not a formula bug) - treated as no data, not
  blocking.`
- `SHB-A.ST: no 52-week range in Excel (confirmed data-provider gap for some
  Nordic-primary tickers, not a formula bug) - treated as no data, not
  blocking.`
- `VOLV-B.ST: no 52-week range in Excel (confirmed data-provider gap for some
  Nordic-primary tickers, not a formula bug) - treated as no data, not
  blocking.`

**And one that is *not* in `flags` and should have been:** `portfolio_deltas`
reads `CASH_SEK (avanza-isk): quantity 15366 -> 20366 (from Excel)`. Only the
15,366 traces to today's confirmed sale; the extra **5,000 SEK has no
documented source** and never became a flag, so it never reached
`claude_excel_prompt.txt`. Every figure in this memo is sized against 15,366.
Second confirmed instance of S9(c) in three sweeps.

---

## Data-gap summary for `meta`

Rolled up from the seven voices' per-pick flags. Ordered by how often they were
named and how much they changed a call.

1. **Look-through holdings for Avanza Global and Avanza Auto 3.** Named by
   Voice 6 as the single metric that would most change its ranking. The
   overlap argument it produced killed **eleven of `scout`'s thirty-two Passed
   names** and it rests on index-construction reasoning, not a fetched holdings
   list — covering 71% of the portfolio. **Not currently an S-item.** Highest
   leverage gap this sweep.
2. **Multi-year FCF / capex series.** Named by Voices 1, 2 and 3, and directly
   load-bearing on the ABB SELL (is 4.4% FCF margin structural or one capex
   year?), on GOOGL and on META. Structural Yahoo limitation, already
   documented in CLAUDE.md — the workaround is the `pdf` skill on a company's
   own cash flow statement.
3. **`sek_per_dkk` missing from the macro block.** Blocks *any* SEK sizing of
   Danish names — NOVO-B.CO, VWS.CO, DSV.CO. This is the reason the memo's
   best fit-adjusted candidate resolves to WATCH. Small, well-scoped fetcher
   addition; `sek_per_eur` is already derived the same way.
4. **`scout`'s screen discards all fundamentals for Failed names, keeping only
   the failing reason.** Directly capped Voice 5's SAAB-B.ST conviction at 4 —
   it could argue the threshold was miscalibrated but could not underwrite the
   company. This gap only became visible because the redesigned method
   requires evaluating all three lists. Output-format fix in the screen writer.
5. **Screen thresholds misapply to specific business models.** `debt_to_equity`
   is meaningless for banks (mislabelled SEB-A.ST and SWED-A.ST as
   Missing-data) and `profit_margins` is meaningless for investment companies
   (failed KINV-B.ST). Four names effectively removed from consideration by a
   filter that does not apply to them.
6. **Swedish CPI stale at 2025M12 (S4).** Named by Voice 7 as its own biggest
   gap. Fourth consecutive sweep capping a live call on a majority-SEK sleeve.
7. **Revenue-by-currency for every holding.** Named by Voice 4 as its biggest
   gap in a DXY-119 regime. Also the scorecard's permanent UNKNOWN row.
8. **The FX unit-mismatch is systematic, not ABB-specific.** The same signature
   — market cap in local currency, revenue and book value in the reporting
   currency, undivided — appears in **HEXA-B.ST** (P/S 46.2, P/B 45.4),
   **SAP** (P/B 65.5), **TSM** (P/B 88.9) and **AZN.ST** (P/S 37.7, P/B 45.9),
   not just ABB. A detection rule (flag P/S or P/B above some multiple of the
   sector norm and re-check the currency fields) would catch all of them at
   once. **New generalization of a previously single-name finding.**
9. **NAV discount/premium for holding companies (S6).** Named by Voices 2 and
   5. Partial workaround found this sweep and worth recording: P/B is a rough
   NAV proxy for *pure* investment companies (INDU-C.ST 0.997x, INVE-A.ST
   1.146x) but **not** for those with wholly-owned operating businesses
   (LATO-B.ST 2.85x), where book is carried at cost.

---

## Learning notes

- **When forward P/E sits *above* trailing P/E, the market is telling you it
  expects earnings to fall.** This showed up four separate times this sweep and
  is one of the cheapest sanity checks available. TEL2-B.ST looks like a
  6.37% -yield defensive holding until you see trailing 11.4 against forward
  25.0 — consensus expects earnings to roughly halve, which is why the yield is
  high. Same signature at AZA.ST (22.4 → 30.8), LIFCO-B.ST (37.3 → 39.6) and,
  in its flat form, ABB.ST (37.6 → 37.1 *while revenue grew 14.2%*, which is
  the margin-compression version of the same message). The reverse is also
  informative: NVDA at 34.5 → 17.6 and TTE at 11.1 → 9.2 are consensus saying
  earnings are rising fast.

- **P/E and PEG can point opposite ways on the same stock, and that conflict
  is the analysis, not a problem to resolve.** Novo Nordisk trades at a P/E of
  11.2 — cheap — and a PEG of 3.11 — expensive. Both are correct: P/E asks
  "what am I paying per krona of *current* earnings" and PEG asks "per krona of
  *growth*." A company with strong current earnings and stalled growth reads
  cheap on one and expensive on the other. The whole investment question
  collapses to which number describes the future, and this system's honest
  answer is "one more quarter of revenue will tell you."

- **Buying an index fund's largest holdings individually concentrates your
  portfolio — it does not diversify it.** Avanza Global is 54.84% of this
  portfolio, and META, GOOGL, NVDA, MSFT, AAPL and six others are already
  inside it. Adding one individually takes on single-company risk (that one
  firm's lawsuit, product miss, or executive departure) in exchange for zero
  new economic exposure. That single structural fact removed eleven of the
  thirty-two names that passed the numeric screen — more than any valuation
  judgment did. It is also why the honest thing to do when you like a mega-cap
  is usually to buy more of the index fund, not the stock.

- **A screening threshold that is right on average is wrong for specific
  business models, and knowing which is a real skill.** This sweep's screen
  used debt/equity above 150 as a fail. That is sensible for a manufacturer
  and meaningless for a bank, whose entire business *is* leverage — which is
  why SEB-A.ST and SWED-A.ST got labelled "missing data" rather than screened.
  Likewise `profit_margins` for an investment company (Kinnevik failed at
  0.0%), and a 40x P/E cap for a defense contractor whose order book runs
  years ahead of its reported earnings (SAAB-B.ST). The right response is not
  to abandon the threshold — it catches real problems most of the time — but
  to be able to say *why* it does not apply to a specific name, and to accept
  that "I can argue the screen is wrong here but I still cannot underwrite the
  company without the data" is a legitimate stopping point.

---

*Reminder: `journal` must run to log this sweep. An unlogged memo is invisible
to the next session and can never be reconciled.*
